Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours

Authors: WN Cooper, RE Dickinson, A Dallol, LB Hesson, I Bieche, GJ Clark, ER Maher, ER Zabarovsky, F Latif

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

RASSF2 is located at 20p13, a region frequently lost in human cancers. RASSF2 is a recently identified member of the ras association domain of family tumour suppressor genes, and many other members of this family are inactivated in human tumours by promoter methylation. …
Metadata
Title
RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours
Authors
WN Cooper
RE Dickinson
A Dallol
LB Hesson
I Bieche
GJ Clark
ER Maher
ER Zabarovsky
F Latif
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1893

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue

Poster presentation

Health inequalities in breast cancer screening

Poster presentation

Primary ductal carcinoma in situmammosphere formation: importance of the epidermal growth factor and Notch receptor signalling pathways

Poster presentation

Altered myoepithelial cell expression and function in cancer-containing breasts

Poster presentation

Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1

Poster presentation

Coactivation of estrogen receptor alpha by the DEAD-box RNA helicases p68 and p72 and its role in breast cancer

Poster presentation

Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits